Background <p>We investigated the benefit of adjuvant radiotherapy in carcinoma endometrium in terms of overall survival (OS) and recurrence free survival (RFS) along with the treatment related toxicities.</p> Methods <p>We conducted a retrospective analysis of 66 patients diagnosed with endometrial</p> <p>cancer who received adjuvant radiotherapy from 2016 to 2019. The treatment modalities included external beam radiotherapy (EBRT), vaginal brachytherapy (VBT), or a combination of both along with chemotherapy for high risk patients. We gathered clinical data and performed statistical evaluations to assess OS, RFS and the incidence of acute and chronic toxicities. Additionally, we compared outcomes based on different EBRT techniques: 3D conformal radiotherapy (3DCRT) and intensitymodulated radiotherapy (IMRT).</p> Results <p>The median follow-up was 60 months (range: 8–95 months). Five-year OS was 84% and five-year Recurrence free survival was 85%. Most of the recurrence were found in intermediate and high risk patients. There was no difference in OS or RFS between the patients who were treated with IMRT or 3DCRT. Adjuvant radiotherapy with 3DCRT had more grade 2, grade3 gastrointestinal toxicity. Two patients who were treated with 3DCRT developed chronic grade 2 proctitis.</p> Conclusions <p>Our findings suggest that adjuvant radiotherapy significantly improves OS and locoregional control in low-and intermediate-risk endometrial cancer patients, while high-risk patients benefit from combined chemoradiation. Patients who were treated with modern radiation techniques like IMRT had less radiation toxicity. However, there was no difference in OS and RFS between 3 DCRT and IMRT.</p>